A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Participants
← catalyst calendarNCT07800897 · readout in 203 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
80estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-09-02
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-26 | estimated | When the study began enrolling |
| Primary completion | 2027-03-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-25 | estimated | The whole study's end, after follow-up |
| First posted | 2026-09-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-09-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Female Adults
Interventions
- Drug: Navlimetostat — also filed as BMS-986504, MRTX-1719
- Drug: Itraconazole
- Drug: Rifampin
- Drug: Midazolam
- Drug: Pantoprazole
Primary outcomes
what the primary-completion date above is the date OFMaximum observed concentration (Cmax) of Navlimetostat
measured Up to approximately 3 weeks
Area under the concentration-time curve from time zero to 192 hours (AUC(0-192)) of Navlimetostat
measured Up to approximately 3 weeks
(AUC(INF)) of Navlimetostat with the coadministration of itraconazole
measured Up to approximately 3 weeks
AUC(INF) of Navlimetostat without the coadministration of itraconazole
measured Up to approximately 3 weeks
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of Navlimetostat
measured Up to approximately 3 weeks
AUC(INF) of Navlimetostat with the coadministration of Rifampin
measured Up to approximately 3 weeks
AUC(INF) of Navlimetostat without the coadministration of Rifampin
measured Up to approximately 3 weeks
Cmax of Midazolam
measured Up to approximately 3 weeks
AUC(0-T) of Midazolam
measured Up to approximately 3 weeks
AUC(INF) of Midazolam with the coadministration of Navlimetostat
measured Up to approximately 3 weeks
AUC(INF) of Midazolam without the coadministration of Navlimetostat
measured Up to approximately 3 weeks
AUC(INF) of Navlimetostat with a high fat meal
measured Up to approximately 3 weeks
AUC(INF) of Navlimetostat without a high fat meal
measured Up to approximately 3 weeks
AUC(INF) of Navlimetostat with the coadministration of Pantoprazole
measured Up to approximately 3 weeks
AUC(INF) of Navlimetostat without the coadministration of Pantoprazole
measured Up to approximately 3 weeks
Drug-related AEs
measured Up to approximately 6 weeks
Related
BMY · their whole pipeline · Who in Congress owns BMY? · Executive-branch trades in BMY
BMY's other studiesmost recently updated first
- Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion Phase 1 · Recruiting
- A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT Phase 1 · Recruiting
- A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors Phase 1/2 · Active, not recruiting
- A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications Phase 3 · Recruiting
- A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India Phase 4 · Active, not recruiting
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed